Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
about
Interventions for actinic keratosesNonsurgical innovations in the treatment of nonmelanoma skin cancerToll-like receptors: the swiss army knife of immunity and vaccine developmentCpG Oligonucleotides as Cancer Vaccine AdjuvantsMolecular cancer prevention: Current status and future directionsImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsPharmacotherapy of actinic keratosis.Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations.Actinic keratosis: rationale and managementIn vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.Toll-like receptor agonists in cancer therapy.Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic KeratosesActinic keratoses: a comprehensive updateNetwork meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.Pharmacotherapy of actinic keratosis: an update.Cutaneous field cancerization: clinical, histopathological and therapeutic aspects.TLR-based immune adjuvants.An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.Resiquimod and other immune response modifiers as vaccine adjuvants.Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities.A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratosesManagement of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians.A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in EuropeCost-utility of first-line actinic keratosis treatments in FinlandMethods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label studyTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Optimal treatment of actinic keratoses.In-office Painless Aminolevulinic Acid Photodynamic Therapy: A Proof of Concept Study and Clinical Experience in More Than 100 PatientsTopical diclofenac in the treatment of actinic keratoses.Solar keratosis: epidemiology, pathogenesis, presentation and treatment.Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.TLR7 and TLR8 as targets in cancer therapy.The use of imiquimod in the treatment of periocular tumours.Emerging drugs for actinic keratosis.Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.Prophylactic and therapeutic implications of toll-like receptor ligands.A review of actinic keratosis for the nurse practitioner: diagnosis, treatment, and clinical pearls.
P2860
Q24202407-3449FD9E-79D2-4A44-87BF-F279A88E32D4Q24632006-CF7E9A6D-D303-46B1-ADB9-B4E20C79C5CFQ26746644-38107051-4AF9-4FE4-89EA-3211B82B0E6FQ26783826-4977381C-F49D-4D35-9C03-25AC431B8F10Q26797207-6C1915EA-8FFE-438E-A63F-D7FA9DEE0163Q28972540-800E3ADC-749A-4EEC-9EAF-067ACAE81E9EQ30898080-C4654EC2-FFB8-46A5-A7FD-437B0C86F9FCQ33293591-5E3F3A3D-763E-4167-8F81-6D79D6569FF9Q33596422-A7FE7C50-9B9E-4C3E-8479-9057151806C8Q33785049-BA540735-B482-49A2-AB29-94D91B76AFA5Q33901007-D2955300-AEC8-4B53-8485-59019F42F08DQ33918509-E15BAD91-50A5-47FA-BDA6-73D9BFF06338Q34074154-E192768D-4B34-463D-AD21-2AF8EF474BC9Q34132659-70EE1E57-922A-417A-B047-C59B53E66812Q34336675-AC1B749C-A6C9-4719-8059-B311DADE4F60Q34378153-2ADB21AE-1033-4566-8202-3613815AB8F8Q34381303-06A7AFE9-7D4E-4477-8C47-CAFC516272F5Q34400322-948CD302-6A88-4DE2-A95B-E1753714DBEAQ34431983-E0C7C467-8163-4A52-AC60-481631892021Q34700325-3411979B-1234-477F-AD69-6AAECE6FD9EDQ34761817-32AFCC3D-1DE7-4EAF-8393-D03433754D0EQ34778360-EA3DB153-60BB-4804-AA34-EFB63B8F7579Q35044103-7B99F9DE-63D7-4074-8825-95D9D902A26FQ35115492-96F691F6-4A5C-444A-BB37-3906B8C0FD7AQ35180653-5541BF6D-1856-44F6-9A29-0AB051113811Q35666250-4A4A7E80-0C71-4811-9021-07DE2E3B8D42Q35767304-7DED6FA0-9213-42F9-A39F-3D7A7B4D223CQ35963938-EE7D048C-67D0-4AB6-B98B-4C0F8FCF945EQ36373370-27A89091-10E0-42DA-82AF-422A151BB625Q36547571-910768C5-8F40-46AE-B8F0-299A97DE636DQ36631465-00B2FE37-5904-4CCC-A2F5-5CB7686DFCEEQ36703886-C597F20F-7FA6-4622-AB7C-ABD3D8DFFDC3Q36834360-571DEF6B-DFD9-4106-9B04-968E9BD0A268Q36973053-FE8E5BB1-3241-4D0E-8183-57F0E1A8C44DQ37051014-EF9F39AC-1CA7-42D6-BB14-C6DDC70FEBCFQ37731551-072A4856-2763-4A53-8BF5-1E028EF2DBA8Q37776509-AD560C33-E188-4D21-A06A-EC583243101FQ37831354-1896D7FE-A412-412C-9DF2-EFBFB20899CFQ37989884-F1631201-906F-416A-8D92-55F12C51C51BQ38007015-F86968E4-78A0-475E-96BA-BCEEDB88D047
P2860
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@ast
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@en
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@nl
type
label
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@ast
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@en
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@nl
prefLabel
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@ast
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@en
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@nl
P2093
P1476
Imiquimod 5% cream for the tre ...... up, vehicle-controlled trials.
@en
P2093
David Whiting
James H Lee
Joseph Jorizzo
Mark Lebwohl
Naji Tawfik
Peter K Lee
Scott Dinehart
Terry L Fox
P304
P356
10.1016/J.JAAD.2003.12.010
P407
P577
2004-05-01T00:00:00Z